Biovie INC

BioVie Inc. stockholders approved an amendment to its 2019 Omnibus Equity Incentive Plan, increasing authorized shares to 3.1 million to enhance talent retention and alignment.

BioVie Inc. announced the results of its 2025 annual meeting, including the election of directors and the approval of an amended equity incentive plan.

BioVie Inc. successfully closed its public offering, raising approximately $12 million in gross proceeds to fund working capital and general corporate purposes.

BioVie Inc. announced the expansion of its Board of Directors from four to six members, appointing Dr. Amy S. Chappell and Kameel D. Farag, effective immediately.

BioVie Inc. has announced that its Board of Directors has approved a one-for-ten reverse stock split of its Class A common stock, effective July 7, 2025, following stockholder approval.

BioVie Inc. stockholders have granted the company's Board of Directors the authority to implement a reverse stock split at a ratio between 1-for-5 and 1-for-10 within the next year.

BioVie Inc. reported a net loss of $5.3 million for the third quarter of fiscal year 2026, an increase from $2.8 million in the prior year, driven by higher research and development expenses for ongoing clinical trials.

BioVie Inc. reported a reduced net loss in its second fiscal quarter, driven by lower operating expenses, while advancing its Parkinson's and Long COVID clinical programs and preparing for a potential liver disease spin-off.

BioVie Inc. reported an increased net loss for Q1 2026, raised $10.5 million in a public offering, and disclosed significant protocol violations in its Alzheimer's Phase 3 trial.

BioVie Inc. announces its financial results for the quarter ended March 31, 2025, and provides updates on its clinical development programs for neurodegenerative and liver diseases.

BioVie Inc. announces its financial results for the quarter ended December 31, 2024, and provides updates on its clinical development programs for neurodegenerative and liver diseases.

BioVie Inc. announced its financial results for the first quarter of fiscal year 2025, ended September 30, 2024, and provided updates on its clinical development programs.

BioVie Inc. reports a reduced net loss but faces substantial doubt about its ability to continue as a going concern, grappling with ongoing securities litigation and past clinical trial integrity issues.

BioVie Inc. released its annual 10-K filing, detailing progress in its clinical programs for neurological disorders and liver disease, along with its financial results for the fiscal year ended June 30, 2024.

BIOVIE Inc.'s Chief Medical Officer, Joseph M Palumbo, was granted 132,000 stock options with an exercise price of $1.31, vesting over several years.

BIOVIE Inc.'s Chief Financial Officer, Joanne Wendy Kim, acquired 110,100 stock options with an exercise price of $1.31, vesting over several years.

BIOVIE Inc. Director Sigmund Rogich was granted 211,100 stock options with an exercise price of $1.31, vesting over various periods.

BIOVIE Inc.'s President and CEO, Cuong V. Do, was granted 665,300 stock options with an exercise price of $1.31, vesting over several years.

BIOVIE Inc. Director Michael Edward Sherman reported the acquisition of 421,100 stock options with an exercise price of $1.31, vesting over several years.

Kameel D. Farag, a Director at BIOVIE INC., was granted 57,500 stock options with an exercise price of $1.31, vesting over time.

BioVie Inc. will hold its 2025 Annual Meeting virtually to elect directors, ratify auditors, and approve a significant increase in shares for its equity incentive plan.

BioVie Inc. has called a Special Meeting of Stockholders for June 23, 2025, to vote on a reverse stock split aimed at increasing its share price to maintain Nasdaq listing compliance and potentially attract institutional investors.

BioVie Inc. has released a supplement to its definitive proxy statement, updating disclosures related to executive and director compensation, outstanding equity awards, and related party transactions.

BioVie Inc. is convening its annual stockholder meeting on November 7, 2024, to vote on key proposals including the election of directors, ratification of the auditor, executive compensation, and an amendment to the equity incentive plan.

BioVie Inc. is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing and enhance the appeal of its common stock.

BioVie Inc. has filed an S-1/A amendment detailing an offering of up to 56,390,977 shares of Class A Common Stock and a similar number of pre-funded warrants.

BioVie Inc. has filed an S-1 registration statement with the SEC to offer shares of Class A Common Stock and pre-funded warrants, aiming to raise capital for general corporate purposes.

BioVie Inc. is offering 1.98 million units of common stock and warrants to raise $13.5 million, while navigating clinical trial challenges and ongoing litigation.

BioVie Inc. announced a public offering to raise approximately $13.5 million for working capital, while grappling with significant clinical trial integrity issues, ongoing litigation, and a 'going concern' warning despite reduced net losses.

BioVie Inc., a clinical-stage biopharmaceutical company, has filed an amended S-1 registration statement for a public offering of units to raise approximately $13.5 million, as it navigates significant clinical trial protocol violations for its Alzheimer's drug candidate and addresses a 'going concern' doubt from its auditors.

BioVie Inc. has filed a registration statement for a public offering of units and pre-funded units, aiming to raise capital for its clinical-stage drug development programs while facing significant dilution and potential Nasdaq delisting risks.

BioVie Inc.'s CEO, Cuong Do, increased his beneficial ownership to 5.03% of Class A Common Stock, while the company amended its 2019 Omnibus Equity Incentive Plan to authorize an additional 3,045,818 shares for awards.

Terren S. Peizer, a significant beneficial owner of BioVie Inc. through Acuitas Group Holdings, LLC, was sentenced to 42 months imprisonment and has filed an appeal, while maintaining a 15.8% stake in the company.

3i, LP, 3i Management LLC, and Maier Joshua Tarlow have filed an amendment to their Schedule 13G, indicating they no longer beneficially own more than five percent of BioVie Inc.'s Class A Common Stock.